|
Roxatidine in duodenal ulcer.
CM Habibullah, MA Habeeb, SP Singh
Dept of Gastroenterology, Osmania Medical College, Osmania General Hospital, Hyderabad.
Correspondence Address:
C M Habibullah
Dept of Gastroenterology, Osmania Medical College, Osmania General Hospital, Hyderabad.
Roxatidine acetate is a new H2-receptor antagonist. A randomized double-blind clinical trial in fifty-three patients with endoscopically proven duodenal ulcers > 5 mm in diameter was undertaken to compare safety and efficacy of roxatidine with that of ranitidine. Twenty-six patients received roxatidine (75 mg bid) while 27 patients received ranitidine (150 mg bid) for 4 weeks. One patient in each group did not come for follow up. Roxatidine and ranitidine had comparable ulcer healing rates (22/25 vs 22/26); roxatidine, however, resulted in greater reduction in the number and severity of night time pain episodes (p < 0.05). No adverse event was reported during 4 weeks of treatment with roxatidine. Thus roxatidine achieves the primary therapeutic goal of relief of pain better than ranitidine.
How to cite this article:
Habibullah C M, Habeeb M A, Singh S P. Roxatidine in duodenal ulcer. J Postgrad Med 1995;41:64-5
|
How to cite this URL:
Habibullah C M, Habeeb M A, Singh S P. Roxatidine in duodenal ulcer. J Postgrad Med [serial online] 1995 [cited 2022 May 26 ];41:64-5
Available from: https://www.jpgmonline.com/article.asp?issn=0022-3859;year=1995;volume=41;issue=3;spage=64;epage=5;aulast=Habibullah;type=0 |
|
|
|
